Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.65 |
| ▸ | LTA4H | P09960 | 3/20 | 0.58 |
| ▸ | PPARG | P37231 | 4/20 | 0.54 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | CPA1 | P15085 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | LAP3 | P28838 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13643128 | 0.87 | MAOB (0.64) | MAOBLTA4HPPARGPPARAFFAR1 | |
| SCHEMBL10509525 | 0.87 | NPC1 (0.51) | MAOBLTA4HNPC1RAB9A | |
| SCHEMBL8298804 | 0.85 | MAOB (0.64) | MAOBLTA4HPPARGPPARAFFAR1 | |
| SCHEMBL6506467 | 0.85 | MAOB (0.64) | MAOBLTA4HPPARGPPARAFFAR1 | |
| SCHEMBL27977003 | 0.81 | LTA4H (0.68) | MAOBLTA4HPPARGPPARAFFAR1 | |
| SCHEMBL21366441 | 0.81 | LTA4H (0.68) | MAOBLTA4HPPARGPPARAFFAR1 | |
| SCHEMBL17931576 | 0.80 | MAOB (0.81) | MAOBLTA4HPPARGPPARAPPARD | |
| SCHEMBL8594326 | 0.80 | MAOB (0.57) | MAOBLTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL392863 | 0.80 | ALOX5 (0.66) | MAOBFFAR1FFAR4NPC1RAB9A | |
| SCHEMBL357349 | 0.80 | MAOB (0.57) | MAOBLTA4HPPARGPPARAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIF5B, KIF2C, PLK1 | MAOB 3045/4885LTA4H 4062/4885PPARG 2756/4885 |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | KIF5B, KIF2C, PLK1 | MAOB 2959/4885LTA4H 4037/4885PPARG 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.